Login to Your Account

Shenogen nabs China rights to Angiochem's paclitaxel-peptide drug conjugate to treat brain metastases from breast cancer

By Shannon Ellis
Staff Writer

Wednesday, January 10, 2018

SHANGHAI – Xinogen (Hong Kong) Pharma Co. Ltd., a subsidiary of Beijing Shenogen Pharmaceuticals Group, has negotiated a deal with Angiochem Inc., of Montreal, to develop and sell ANG-1005, a paclitaxel-peptide drug conjugate for the treatment of leptomeningeal carcinomatosis from breast cancer. The deal gives Xinogen rights for greater China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription